Read our latest updates & insights

In an effort to “champion equitable access to medicine” Brazil and India have entered into a series of agreements to support Brazilian domestic manufacture of publicly funded oncology medicines.

On 21 February 2026, it was announced at the India-Brazil Business Forum...

During its Q3 FY26 Earnings Call on 10 February 2026, Zydus Lifesciences indicated that it is hoping to be the first to file a Biologics Licence Application in the US for a pembrolizumab biosimilar and may potentially be first to launch in the US, subject to regulatory appr...

On 5 February 2026, CVS Health announced that pharmacy benefits manager, CVS Caremark, will begin offering Samsung Bioepis’ Ospomyv® and Celltrion’s Stoboclo®, biosimilars to Amgen’s Prolia® (denosumab), on major US national commercial template formularies from 1 April 2026...

On 5 February 2026, Korea Biomedical Review reported that Korean headquartered HK inno.N has received approval from Korea’s Ministry of Food and Drug Safety for Izambia Prefilled Syringe and Denbrayce Injection, biosimilars to Amgen’s Prolia® and Xgeva® respectively.

On 5 February 2026, Alvotech announced positive results from a pharmacokinetic study for AVT80, biosimilar to Takeda’s Entyvio® (vedolizumab).

The Phase 1 study evaluated the comparative pharmacokinetics, safety, immunogenicity and tolerability between AVT80 and Enty...